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volumes in treated volumes depended on
bladder fillings. CONCLUSIONS Implementation
of 3D treatment planning system in teletherapy
of cervical cancer helps to avoid a geographical
miss, to reduce both the treated volume and the
doses delivered to organs at risk.
10.
THE COMPARISON BETWEEN THE
THREE - FIELD AND FOUR-FIELD
TECHNIQUES OF PLANNING OF
RADIOTHERAPY IN PROSTATE
CANCER
P. Milecki, T. Piotrowski, M. Dymnicka,
J. Malicki, G. Stryczyńska
Greatpoland Cancer Centre, Poznań, Poland
Purpose: evaluation 3-field(3F) and 4-field(4F)
planning techiniques for patients with localized
prostate cancer. Materials/methods: Five
patients with prostate cancer (T3NOMO) were
evaluated. CT images were obtained at 5mm
increments and were transferred to
CadPlan_planning_workstation. The planning
target volume (PTV) was detined as prostate
and seminal vesicles with 15mm margins
around c1inical target volume (CTV) except
prostate-rectum interface where 5mm margin
was applied. CTV was detined as prostate and
seminal vesicles.Following organs at risk (CAR)
were outlined: rectum, bladder, right temaral
head. Following 3F and 4F plans were
performed: 3F with angles (Odeg-120deg-
240deg; Odeg-90deg-270deg) and 4F (Odeg-
90deg-180deg-270deg). We also created two
versions ot treatment plans including ot energy;
6MV and 20MV for Clinac2300CD. Total dose
was 74Gy. Mean total doses ot thirty plans in
irradiated organs at risk (rectum, bladder and
righ temoral head) were compared. For PTV
mean and minimum dose were criteria tor
comparision ot treatment plans. Results: There
were no significant dose differenes between
evaluated plans ot treatment in PTV(0.05).
Secause mean dose in femoral head in each
treatment plan was below tolerance dose, main
dose-Iimiting organ was rectum and bladder.
Lowest mean dose 42.7 Gy in rectum was
achived by application ot 3F technique ot
20MV(Odeg-90deg-270deg). SIadder was also
spared with the same 3F technique of 20MV,
where mean dose was 45.2Gy. Conclusions:
This study showed that the "T" three-tield
technique (an anterior and two opposing lateral
tields) provided with 20 MV is optimal and
assures the lowest rectal dose.
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11.
THE ANALYSIS OF DOSES IN THE
TUMOUR AND IN CRITICAL TISSUES
IN THE BRACHYTHERAPY OF
MALIGNANT MELANOMA LOCALlSED
IN EYES
J. Kierzkowski1, J. Malicki1, A. Roszak2
l Medical Physics Department and 2Srachytherapy
Ward, Greatpoland Cancer Centre, Garbary 15
Street, 61-866 Poznań, Poland.
Srachytherapy is known and used procedure
in the treatment of tumours localised in eyes,
especially recommended when avoiding ot
enucleation accompany the long term cure.
Aim: The aim ot this paper was to compare
the doses delivered to the tumour and critical
tissues during the treatment of the group ot
patients treated with Ru-106 applicator.
Patients: Setween 1994 and 2000, 67
patients (dgn. melanoma malignum in eye)
underwent brachytherapy. At 51 patients the
tumour was localized in the back ot eye, at 15
equatorially and at one in the tront section ot the
eyeball. The median ot the patients' age was
56.3 years. The CCS type applicator was
applied for 56 patients, the COS for 7 and the
ROA tor 4 patients.
Method: Irradiation - Prescribed dose of 60
Gy was normalized to the top ot the tumour, it
decreased by 50%-10% per millimetre with the
distance trom applicator. The isotope producer
determined the dose-rate accuracy tor +/-30%.
This caused that therapeutic dose had to be
calculated taking account tor the minimai dose-
rate, while the doses in critical organs for
maximai dose-rate possible.
Analysis: Ali patients were divided into three
subgroups: 8 patients into 1sI , 19 into 2nd and 40
into 3rd • The inclusion criterion was size of
tumour: up to 3 mm of height (1 S1 group), 3-5
mm (2nd), and larger than 5 mm (3rd)
respectively.
Results: Table presents mean doses in the
tumour, selera and lens (calculated at it's
middle) tor each group ot patients.
Tumour Doses [Gy]
size
[mm] Tumour Selera lens
<3 102.9 162.4 137.6
3-5 186.2 463.5 396.2
>5 268.2 974.9 840.6
31
Conclusions: Mean doses in tumour varied
from 102.9 Gy to 268.2 Gy depending on the
tumour size. Doses in selera and lens did not
exceed the tolerance levels in all three groups ot
patients.
12.
THE EVALUATION OF CLINICAL,
HISTOLOGICAL AND MOLECULAR
PREDICTIVE AND GROGNOSTIC
FACTORS IN PATIENTS WITH
ADVANCED SaUAMOUS CELL
CANCER OF THE LARYNX, MESO-
AND HYPOPHARYNX, FLOOR OF
MOUTH IRRADIATED AFTER
INDUCTION CHEMOTHERAPY
K. Małecki
Centrum Onkologii, Klinika Radioterapii Kraków,
Polska
Setween 1988-1997198 patients with HNSCC
received induction chemotherapy. Clinical
staging was as follows 11-7(52%), 111-45(20%),
IV-146(64%). Patients received 1 to 4 cycles of
Cisplatin + 5FU. Response to chemotherapy
(CR or PRl was observed only in patients who
received 2-4 cycles ot chemotherapy. The best
responses were observed in patients with
laryngeal, mesopharyngeal and hypopharyngeal
cancers, 55%. Radiotherapy was subsequently
performed in 178(90%). Twenty patients were
not irradiated because of poor performance
status or progression ot disease after
chemotherapy. Radical radiotherapy was
performed in 124 (5-year LC 38%, DFS 35%,
DSS 43%, OS 30%). Ali 25 patients irradiated
palliatively dyied during 26 months. The best
results were observed in patients with laryngeal
cancer; LC 48%, DFS 25%, DSS 32%, OS 22%.
The most trequent failure was local recurrence
in 29(23%) patients. In the next step of this
study we want; 1) to assess prognostic and
predictive value ot selected clinical, histological
and molecular factors by detining its influence
on the chance ot response to chemotherapy and
chance of cure 2) to examine the correlation
between theses factors and to establish if they
give new predictive and prognostic intormation
3) to establish which ot examined factors may
be usetul in selecting patients with advanced
HNSCCs to combined modality treatment
(chemotherapy + radiotherapy), and particularily
32
in selecting patients with advanced laryngeal
cancer to larynx preservation treatmenł. We will
examine the celi cycle parameter Ki67,
expression ot p53 protein and expresion ot
(EGFr). There will be also reevaluated
histological material (grading).
13.
IMMUNOGENETHERAPY COMBINED
WITH BRAIN METASTASES
IRRADIATION IN MELANOMA
PATIENTS
S. Nawrocki, A. Karczewska, P. Mileckl,
O. lżycki, G. Stryczyńska, A. Mackiewicz
Greatpoland Cancer Centre, USaMS, Poznań,
Poland
Aims: To assess toxicity and results ot
melanoma brain metastases irradiation in
patients treated with genetically moditied tumour
vaccine.
Materials/methods: A group of 45 melanoma
stage IV (AJCC) patients was treated with
vaccine consisted of autologic melanoma cells
admixed with allogeneic cells modified with IL-6
and sIL-BR genes. During the treatment 14
patients developed symptoms ot brain
metastases. 5 patients had solitary metastases,
9 multiple lesions. 4 patients with single
metastasis were treated surgically. Ali 14
patients were irradiated with the doses 30-39
Gy, using 3 Gy/tracion, 5 fractions/week.
Toxicity of cranial irradiation (c1inically, eT) and
clinical results (CT, survival) were evaluated.
Immunological cellular responses were
assessed in vitro.
Results: Acute effects ot irradiation were
tolerable and manageable using standard
dexamethasone treatment. There was no
radiation encephalopathy or radiation necrosis.
In 7/14 patients stabilization er partial remission
of brain lesions was observed. Overall survival
measured trom brain metastases diagnosis
ranged from 2 to 21 months (2 patients are stil!
alive), median survival was 316 days. In 4
treated patients radiation enhanced immune
responses to the vaccine.
Conclusions: Palliative cranial irradiation is
well tolerated by patients treated with novel
systemie approaches such as immunogene
therapy, relives symptoms and may extend
survival. Radiation ot metastases modulates
immune responses to melanoma cells.
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